Trials / Completed
CompletedNCT01322269
A Study of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- HemaQuest Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 12 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of three dose levels of HQK-1001 administered once daily for 26 weeks in subjects with sickle cell disease.
Conditions
- Sickle Cell Disease
- Sickle Cell Anemia
- Sickle Cell Disorders
- Hemoglobin S Disease
- Sickling Disorder Due to Hemoglobin S
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HQK-1001 | HQK-1001 tablets, once daily for daily 26 weeks |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-03-01
- First posted
- 2011-03-24
- Last updated
- 2013-06-19
Locations
16 sites across 5 countries: United States, Canada, Egypt, Jamaica, Lebanon
Source: ClinicalTrials.gov record NCT01322269. Inclusion in this directory is not an endorsement.